Failed trial puts future of UCB’s epilepsy drug padsevonil in doubtShares in UCB slid this morning after the Belgian company announced its refractory epilepsy drug candidate padsevonil had Share XFailed trial puts future of UCB’s epilepsy drug padsevonil in doubthttps://pharmaphorum.com/news/failed-trial-puts-future-of-ucbs-epilepsy-drug-padsevonil-in-doubt/
UCB’s James Musick on embracing digital therapeuticsDigital has rapidly taken over the pharma industry, but many still don’t fully understand how to harness it. Share XUCB’s James Musick on embracing digital therapeuticshttps://pharmaphorum.com/views-analysis-digital/ucbs-james-musick-on-embracing-digital-therapeutics/
Janssen trials ultrasound-guided approach to treating Crohn’sIn the highly competitive market for inflammatory diseases such as Crohn’s, pharma companies are looking for ways to Share XJanssen trials ultrasound-guided approach to treating Crohn’shttps://pharmaphorum.com/news/janssen-trials-ultrasound-guided-approach-to-treating-crohns/
UCB/Amgen’s Evenity approved in Europe after appealUCB and Amgen’s osteoporosis drug Evenity has finally been approved in Europe, following a successful appeal against a Share XUCB/Amgen’s Evenity approved in Europe after appealhttps://pharmaphorum.com/news/ucb-amgens-evenity-approved-in-europe-after-appeal/
UCB posts more supportive data from Humira rival bimekizumabThere’s a whole gang of pharma companies queueing up to steal market share from AbbVie’s mega-blockbuster Humira, and Share XUCB posts more supportive data from Humira rival bimekizumabhttps://pharmaphorum.com/news/ucb-posts-more-supportive-data-from-humira-rival-bimekizumab/
Improving medicines adherence with VRWith medicine adherence still a major problem for pharma and healthcare systems, a collaboration between Cognitant Group and Share XImproving medicines adherence with VRhttps://pharmaphorum.com/views-analysis-digital/improving-medicines-adherence-vr/
Patient voice overcomes EU ‘no’ for UCB/Amgen’s osteoporosis drugUCB/Amgen’s osteoporosis drug Evenity (romosozumab) looks set for approval in Europe after regulators finally recommended it, following a Share XPatient voice overcomes EU ‘no’ for UCB/Amgen’s osteoporosis drughttps://pharmaphorum.com/news/ucb-overcomes-eu-no-for-osteoporosis-drug-with-patient-testimony/
UCB’s bimekizumab tops J&J’s Stelara in psoriasis studyThe first phase 3 data with UCB’s key pipeline drug bimekizumab show that it hit all its efficacy Share XUCB’s bimekizumab tops J&J’s Stelara in psoriasis studyhttps://pharmaphorum.com/news/ucbs-bimekizumab-tops-jjs-stelara-in-psoriasis-study/
UCB sets sights on rare diseases giant Alexion with Ra Pharma acquisitionUCB is to buy US biotech Ra Pharma in a deal worth around $2.1 billion, adding a late-stage Share XUCB sets sights on rare diseases giant Alexion with Ra Pharma acquisitionhttps://pharmaphorum.com/news/ucb-takes-on-rare-diseases-giant-alexion-with-ra-pharma-acquisition/
